We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.
- Authors
Peralta Alvarez, Marco Polo; Jones, Holly; Redondo Azema, Hugo; Davis, Chloe; White, Andrew D.; Sarfas, Charlotte; Dennis, Mike; Shuailin Li; Wright, Daniel; Puentes, Eugenia; Kimuda, Simon; Belij-Rammerstorfer, Sandra; Aguilo, Nacho; Martin, Carlos; Sharpe, Sally; McShane, Helen; Tanner, Rachel
- Abstract
Introduction: Mycobacteria are known to exert a range of heterologous effects on the immune system. The mycobacteria-based Freund's Complete Adjuvant is a potent non-specific stimulator of the immune response used in immunization protocols promoting antibody production, and Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccination has been linked with decreased morbidity and mortality beyond the specific protection it provides against tuberculosis (TB) in some populations and age groups. The role of heterologous antibodies in this phenomenon, if any, remains unclear and under-studied. Methods: We set out to evaluate antibody responses to a range of unrelated pathogens following infection with Mycobacterium tuberculosis (M.tb) and vaccination with BCG or a candidate TB vaccine, MTBVAC, in non-human primates. Results: We demonstrate a significant increase in the titer of antibodies against SARS-CoV-2, cytomegalovirus, Epstein-Barr virus, tetanus toxoid, and respiratory syncytial virus antigens following low-dose aerosol infection with M.tb. The magnitude of some of these responses correlated with TB disease severity. However, vaccination with BCG administered by the intradermal, intravenous or aerosol routes, or intradermal delivery of MTBVAC, did not increase antibody responses against unrelated pathogens. Discussion: Our findings suggest that it is unlikely that heterologous antibodies contribute to the non-specific effects of these vaccines. The apparent dysregulation of B cell responses associated with TB disease warrants further investigation, with potential implications for risk of B cell cancers and novel therapeutic strategies.
- Subjects
BCG vaccines; ANTIBODY titer; B cell lymphoma; MYCOBACTERIUM tuberculosis; MYCOBACTERIAL diseases; HUMAN metapneumovirus infection
- Publication
Frontiers in Immunology, 2024, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2024.1387454